SPERO THERAPEUTICS INC. - COMMON STOCK

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

14 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024

07 Nov 2024 15:05:01 By Nasdaq GlobeNewswire

Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update

29 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

16 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

02 Oct 2024 15:30:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Present at Upcoming September Investor Conferences

04 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

05 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

29 Jul 2024 15:05:16 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 Jul 2024 12:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 Jun 2024 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

16 May 2024 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

15 May 2024 15:05:37 By Nasdaq GlobeNewswire

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

08 May 2024 07:00:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 May 2024 15:07:35 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

13 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

06 Mar 2024 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

28 Feb 2024 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference

26 Feb 2024 07:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Spero Therapeutics Provides Corporate Update and 2024 Outlook

05 Jan 2024 07:05:00 By Nasdaq GlobeNewswire